In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 150 of 451

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance	TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091	Technology appraisal guidance	TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Osteoporosis	Quality standard	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC
Pegcetacoplan for treating geographic atrophy [ID4041]	Technology appraisal guidance	TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance	TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]	Technology appraisal guidance	TBC
Digital technologies to support smoking cessation in secondary care patients: early value assessment	Health technology evaluation	TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Psoriasis: assessment and management (CG153)	NICE guideline	TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]	Technology appraisal guidance	TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473	Technology appraisal guidance	TBC
Alcohol Use Disorders (update)	NICE guideline	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	TBC
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance	TBC
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]	Technology appraisal guidance	TBC
DCVax-L for treating glioblastoma [ID836]	Technology appraisal guidance	TBC

Results per page

10
25
50
All